MALIGNANT SOLID TUMOR
Clinical trials for MALIGNANT SOLID TUMOR explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT SOLID TUMOR trials appear
Sign up with your email to follow new studies for MALIGNANT SOLID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug GEN1078 tested in just 3 people – trial halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called GEN1078 in 3 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check for side effects and see how the body processes the drug. The trial was terminated early, so r…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New antibody combo tackles solid tumors in early trial
Disease control TerminatedThis early-phase trial tested a new antibody drug, GEN1055, in 21 adults with advanced solid tumors. The goal was to check safety and find the right dose when used alone or with pembrolizumab (with or without chemotherapy). The study was stopped early, but results help guide futu…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo tested for tough cancers
Disease control TerminatedThis early-stage study tested a new drug called ZL-1218, alone or with another cancer drug, in 34 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, side effects, and how the drug moves through the body. The …
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1 • Sponsor: Zai Lab (Hong Kong), Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New PET tracer aims to light up tumors, but trial stalls
Diagnosis TerminatedThis early-phase trial tested a radioactive imaging agent called 68GaNOTA-Anti-MMR-VHH2 to see if it could safely highlight tumors on PET scans. It involved 13 adults with advanced solid tumors, breast cancer, or melanoma. The study was terminated early, so we have limited inform…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC